Long-term tracking of patients with chronic blood cancers has shown that hidden genetic changes can shape how a disease develops years before symptoms get worse. This research followed patients over time, revealing key genetic differences between blood cancers that stay stable and those that become more aggressive.
These findings suggest that DNA data could help make diagnoses more accurate. It could also improve how patients are monitored and give doctors a clearer view of how treatments are working. This points to a future where regular genetic testing is a bigger part of standard healthcare.
Uncovering Cancer's Hidden Paths
Scientists from the Wellcome Sanger Institute and their partners studied genetic data and medical records from patients with chronic blood cancers. They traced the history of blood cells to see how these diseases develop over decades. This study was published in Cancer Discovery and presented at the American Association of Cancer Research (AACR) Conference.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxMyeloproliferative neoplasms (MPNs) are a type of chronic blood cancer. These rare conditions start in the bone marrow, where too many blood cells are made. About 40,000 people in the UK have MPNs, and about 4,000 new cases are found each year. These conditions usually progress slowly and are caused by DNA changes that can appear early in life and build up over time.
Most MPN cases are linked to changes in the JAK2, CALR, or MPL genes. However, about 10% of patients do not have these genetic changes. For these patients, diagnosis often depends on how bone marrow cells look under a microscope. This means some patients might get treatments like chemotherapy without clear genetic proof of cancer.
Predicting Disease Progression
The way these cancers progress varies a lot. Some patients stay stable for years and need little treatment. Others develop more serious conditions like leukemia or scarring in the bone marrow. Doctors currently find it hard to predict which path a patient's disease will take.
To help with this, the research team looked at whether genetic analysis could predict disease progression. They also wanted to clarify if patients without common mutations truly have cancer.
They followed 30 patients with chronic blood cancers, mostly MPNs. They combined whole genome sequencing with detailed medical records. The data included almost 8,000 blood test results, treatment histories, and disease outcomes. In total, over 450 samples were analyzed, with some patients monitored for up to 25 years.
By linking long-term clinical follow-up with genomic analysis, the team tracked how blood cell populations changed. They used DNA to build cellular "family trees." This helped them find where cancer clones, which are groups of identical cells that drive disease progression, came from.
Clear Differences in How Cancers Evolve
The study showed clear differences in how these cancers evolve. Patients whose disease stayed stable had blood cells that remained genetically consistent, meaning they didn't get new mutations. In contrast, patients whose condition worsened showed a steady increase in DNA changes over time.
These results suggest that the disease's path is often set years in advance. Early genetic signals can appear long before symptoms are noticeable.
The researchers also looked at patients who didn't have the usual genetic markers for MPNs. By studying "family trees" from about 200 blood cell genomes, they found patterns that matched normal aging, not cancer.
This finding challenges the idea that all patients with certain bone marrow features have true blood cancer. It suggests some people might be misdiagnosed and could benefit from different care. These results support new guidelines for evaluating patients without JAK2, CALR, or MPL mutations, aiming to improve diagnosis and care.
Hope for Future Treatments
The study highlights how important genomic data is becoming in cancer care. It shows its potential to guide more precise treatments. Researchers believe regular genetic testing could one day help find patients at high risk of progression years earlier. This would allow doctors to intervene sooner.
Dr. Daniel Leongamornlert, the first author, explained that they followed MPN patients for many years. They used genome sequencing and clinical history to trace how blood cell populations changed. By reconstructing cell ancestry, they saw different patterns between stable and progressing diseases.
Dr. Dani Skirrow from Cancer Research UK noted that technology now allows rapid DNA reading to find errors that cause cancer. She said this research helps build a detailed picture of how blood cancers start and grow. It reveals changes that could help predict cancer years ahead.
This type of discovery research is vital for improving how we monitor people at risk of blood cancer. It also helps find better ways to prevent, detect, and treat the disease, so people can live longer, better lives.
Dr. Jyoti Nangalia, a senior author and consultant hematologist, said it's hard to predict how these cancers might change. By combining long-term care with regular genomic analysis, they could watch the genetic code evolve before clinical changes. She believes these patterns will help doctors create better monitoring strategies, refine diagnoses, and lead to better patient outcomes.
Alan Everitt, 77, was diagnosed with essential thrombocythaemia (ET), an MPN, in 1992. His condition progressed to myelofibrosis and recurring skin cancers. He hopes his participation in this research will help future patients whose cancer is likely to progress.
Deep Dive & References: Genomic evolution and natural history of myeloproliferative neoplasms on therapy - Cancer Discovery, 2026
